Mesothelioma Clinical Trials in Chicago, Illinois

6 studies are recruiting for mesothelioma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 124, Chicago, Illinois

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

2. A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

   The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago (Data Collection Only), Chicago, Illinois

   Locations

   13 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06057935 on ClinicalTrials.gov

3. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

4. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

   This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   12 in total

   Run by

   Vivace Therapeutics, Inc

   See if you can join NCT04665206 on ClinicalTrials.gov

5. Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

   Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able to be removed completely. This is called unresectable cancer. This stud…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07126509 on ClinicalTrials.gov

6. Olaparib in Patients With HRD Malignant Mesothelioma

   In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT04515836 on ClinicalTrials.gov